
Commentary|Videos|December 8, 2024
Dr Mauz-Koerholz on the Role of Pembrolizumab in Younger Patients With Low-Risk Classic Hodgkin Lymphoma
Author(s)Christine Mauz-Koerholz, MD, PhD
Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.
Advertisement
Christine Mauz-Koerholz, MD, PhD, Department of Pediatric Hematology and Oncology, Martin Luther University Halle-Wittenberg, discusses updated results from the phase 2 KEYNOTE-667 trial (NCT03407144) of pembrolizumab (Keytruda) in children, adolescents, and young adults with low-risk classic hodgkin lymphoma and slow early response to front line chemotherapy. These findings were presented at the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5


































